Ketamine has gained increasing attention for its therapeutic potential, yet concerns remain regarding its misuse and the associated complications of its use. Ketamine use and ketamine use disorder can induce psychotic symptoms, but the persistence of such symptoms with chronic use and effective treatment of these symptoms is poorly characterized. Although case reports of ketamine use and...
Little is known about the correlates of repeated non-medical lysergic acid diethylamide (LSD) use. Therefore, we aimed to determine the prevalence and correlates of past-year LSD use among people aged 18 years and older in the United States who first used LSD at least 5 years ago. Using data from the 2015-2019 National Survey on Drug Use and Health, we examined the estimated weighted prevalence...
Objective: While data on perceived availability of lysergic acid diethylamide (LSD) [paLSD] are collected annually in the United States, detailed investigations of recent trends in paLSD have not been published. Therefore, we sought to explore this topic. Method: Data were sourced from the 2015–2019 National Survey on Drug Use and Health (NSDUH) administrations. To identify factors associated...
Objective: This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the United States using nationally representative data and to compare correlates of LSD use between lesbian, gay, and bisexual individuals (LGB) and heterosexual individuals. Method: Using National Survey on Drug Use and Health data on adults from 2015 to...
This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted therapy (PAT). In 2023, we distributed an anonymous survey to United States psychiatry residents, assessing demographics, knowledge, and opinions on psychedelics/PAT. The survey also included items asking respondents to retrospectively self-report...
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...
Within substance use research, religion and spirituality (r/s) have been understudied in relation to harm reduction approaches. We perform a literature review to characterize various intersections between r/s and harm reduction. We searched major databases, Google Scholar, and other sources for academic articles and gray literature on the intersection between r/s and harm reduction. We describe...
The current opioid crisis has had an unprecedented public health impact. Approved medications for opioid use disorder (OUD) exist, yet their limitations indicate a need for innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most clinical evidence remains observational, with few controlled trials. This review aims to bridge...
The rise of psychedelics in contemporary medicine has sparked interest in their potential therapeutic applications. While traditionally associated with countercultural movements and recreational use, recent research has shed light on the potential benefits of psychedelics in various mental health conditions. In this review, we explore the possible role of psychedelics in the management of...
Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, little scholarly work exists on whether perceived risk of trying LSD (prLSD) is changing or factors influencing prLSD among the general public. Therefore, we sought to investigate changes in prLSD from 2015 to 2019 and identify characteristics...
Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually...
Abstract Background Lysergic acid diethylamide (LSD) use has risen in the United States in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the United States and investigate recent demographic...
October 30, 2023Jeremy Weleff, Julio C Nunes, Gabriel P. A. Costa et al.
The rise of psychedelics in contemporary medicine has sparked interest in their potential therapeutic applications. While traditionally associated with countercultural movements and recreational use, recent research has shed light on the potential benefits of psychedelics in various mental health conditions. In this review, we explore the emerging role of psychedelics in the management of...
Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...
Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca,...
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is limited. A growing body of online media claims that individuals have noticed improvement in anosmia and microsmia following classic psychedelic use. We report what we believe to be the first three cases recorded in the academic literature of...
Abstract Objectives A resurgence of research investigating the administration of psychedelic compounds alongside psychotherapy suggests that this treatment is a promising intervention for anxiety, depression, and existential distress in people with cancer. However, psychedelic treatment that induces a mind-altering experience potentially poses barriers to vulnerable cancer patients, and...
Following a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as psychiatric treatments. The academic journals, institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of psychedelics have only recently begun to be investigated. To expand upon this work, we...
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...
Background. Clinical trials have demonstrated that subanesthetic intravenous ketamine exerts antidepressant effects lasting a week or longer postinfusion, as well as antisuicidal effects starting approximately 4 hours postinfusion and lasting 72 hours or longer. These findings have generated considerable enthusiasm within psychiatry. However, reports of treatment-emergent suicide attempts and...
Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addictions. While most of this work has been privately funded, governmental biomedical research funding bodies in countries...
Dataset for a bibliometric analysis of journal articles reporting findings from clinical studies of the psychedelics 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), ayahuasca, dimethyltryptamine (DMT), ibogaine, lysergic acid diethylamide (LSD), mescaline, MDMA, and psilocybin published from 1965-2018.This data accompanies our article:Bibliometric Analysis of Academic Journal Articles Reporting...